Topical therapy for actinic keratoses, I: 5-Fluorouracil and imiquimod

Cutis

Volumn 71, Issue 5, 2003, Pages 365-370+372

  Tutrone, William D ^a,d   Saini, Ritu ^b   Caglar, Selin ^a   Weinberg, Jeffrey M ^c   Crespo, Jorge ^d  

^a UNIVERSITY OF VERMONT   (United States)

^b NEW YORK UNIVERSITY   (United States)

^c Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLCHICINE; DICLOFENAC; FLUOROURACIL; IMIQUIMOD; RETINOID; AMINOQUINOLINE DERIVATIVE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE;

ACTINIC KERATOSIS; CLINICAL FEATURE; CLINICAL TRIAL; COLITIS; CREAM; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG MECHANISM; DRUG URINE LEVEL; DRY SKIN; EROSION; ERYTHEMA; FACE; HUMAN; PRURITUS; REVIEW; SIDE EFFECT; SKIN ABSORPTION; SKIN ALLERGY; SKIN BURNING SENSATION; SKIN IRRITATION; SKIN MANIFESTATION; SKIN ULCER; CONTROLLED CLINICAL TRIAL; INTRADERMAL DRUG ADMINISTRATION; KERATOSIS; PATHOLOGY; PRECANCER; RANDOMIZED CONTROLLED TRIAL; SKIN TUMOR;

ADMINISTRATION, CUTANEOUS; AMINOQUINOLINES; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; FLUOROURACIL; HUMANS; KERATOSIS; PRECANCEROUS CONDITIONS; RANDOMIZED CONTROLLED TRIALS; SKIN NEOPLASMS;

EID: 0041413029     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Feldman SR, Fleischer AB Jr, McConnell C. Most common dermatologic problems identified by internists. 1990-94. Arch Intern Med. 1998;158:726-730.
2. Dubreuilh W. Des hyperkeratosis circonscrites. In: Pringle JJ, ed. Third International Congress of Dermatology: Official Transactions. London, England: Waterlow and Sons; 1898:125-176.
3. Ziegler A, Jonason AS, Leffell DJ, et al. Sunburn and p53 in the onset of skin cancer. Nature. 1994;372:773-776.
4. Nelson MA, Eiknspahr JG, Alberts DS, et al. Analysis of p53 gene in human precancerous actinic keratosis lesions and squamous cell cancers. Cancer Lett. 1994;85:23-29.
5. Marks R, Jolley D, Lectsas S, et al. The role of childhood exposure to sunlight in the development of solar keratoses and non-melanocytic skin cancer. Med J Aust. 1990;152:62-66.
6. Engel A, Johnson ML, Haynes SG. Health effects of sunlight exposure in the United States. Results from the first National Health and Nutrition Examination Survey, 1971-1974. Arch Dermatol. 1988;124:72-79.
7. Marks R, Foley P, Goodman G, et al. Spontaneous remission of solar keratosis: the case for conservative management. Br J Dermatol. 1986;115:649-655.
8. Marks R, Rennie G. Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet. 1988;1:296-297.
9. Dodson JM, DeSpain J, Hewett JE, et al. Malignant potential of actinic keratoses and the controversy over treatment, a patient-oriented perspective. Arch Dermatol. 1991;127:1029-1031.
10. Simmonds WL. Double-blind investigation comparing a 1%- vs -5% 5-fluorouracil topical cream in patients with multiple actinic keratoses. Cutis. 1973;12:615-617.
11. Levy S, Furst K, Chem W. A comparison of the skin permeation of three topical 0.5% fluorouracil formulations with that of a 5% formulation. Clin Ther. 2001;23:901-907.
12. Levy S, Furst K, Chern W. A pharmakokinetic evaluation of 0.5% and 5% fluorouracil topical cream in patients with actinic keratosis. Clin Ther. 2001;23:908-919.
13. Loven K, Stein L, Furst K, et al. Evaluation of the efficacy and tolerability of 0.5% fluorouracil cream and 5% fluorouracil cream applied to each side of the face in patients with actinic keratosis. Clin Ther. 2002;24:990-1000.
14. Weiss J, Menter A, Hevia O, et al. Effective treatment of actinic keratosis with 0.5% fluorouracil cream for 1, 2, or 4 weeks. Cutis. 2002;70(suppl 2):22-29.
15. Robins P, Gupta AK. The use of topical fluorouracil to treat actinic keratosis. Cutis. 2002;70(suppl 2):4-7.
16. Chabner BA, Allegra CJ, Curth GA, et al. Antineoplastic agents: pyrimidine analogs. In: Hardman JG, Limberd L, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill; 1996:1247-1251.
17. Dinehart SM. The treatment of actinic keratoses. J Am Acad Dermatol. 2000;42:S25-S28.
18. Jansen GT. Topical therapy with 5-fluorouracil. J Surg Oncol. 1971;3:317-323.
19. Gupta AK. The management of actinic keratoses in the United States with topical fluorouracil: a pharmacoeconomic evaluation. Cutis. 2002;70(suppl 2):30-36.
20. Goette DK, Odom RB, Owens R. Allergic contact dermatitis from topical fluorouracil. Arch Dermatol. 1977;113:196-198.
21. Johnson MR, Hageboutros A, Wang K, et al. Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin Cancer Res. 1999;5:2006-2011.
22. Beutner KR, Geisse JK, Helman D, et al. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol. 1999;41:1002-1007.
23. Slade HB. Cytokine induction and modifying the immune response to human papilloma virus with imiquimod. Eur J Dermatol. 1998;8:13-16.
24. Edwards L, Ferenczy A, Eron L, et al. Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. human papilloma virus. Arch Dermatol. 1998;134:25-30.
25. Kono T, Kondo S, Pastore S, et al. Effects of a novel topical immunomodulator, imiquimod, on keratinocyte cytokine gene expression. Lymphokine Cytokine Res. 1994;13:71-76.
26. Miller R, Birmachu W, Gerster J, et al. Imiquimod: cytokine induction and antiviral activity. Int Antiviral News. 1995;3:111-113.
27. Flowers F. Imiquimod in the treatment of actinic keratoses and other intraepithelial neoplasms. Int J Dermatol. 2002;41(suppl)1:12-15.
28. Salasche SJ, Levine N, Morrison L. Cycle therapy of actinic keratoses of the face and scalp with 5% topical imiquimod cream: an open-label trial. J Am Acad Dermatol. 2002;47:571-577.
29. Persaud AN, Shamuelova E, Sherer D, et al. Clinical effect of imiquimod 5% cream in the treatment of actinic keratosis. J Am Acad Dermatol. 2002;47:553-556.
30. Stockfleth E, Meyer T, Benninghoff B, et al. Successful treatment of actinic keratosis with imiquimod cream 5%: a report of six cases. Br J Dermatol. 2001;144:1050-1053.
31. Stockfleth E, Meyer T, Benninghoff B, et al. A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses. Arch Dermatol. 2002;138:1498-1502.